Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-0,21%
1 091,51
-2,30
-0,21%
—1 093,811 096,521 100,221 091,51——
SIXC
Communications
SIXC
Communications
SIXC
+0,22%
610,11
+1,34
+0,22%
—608,77608,77612,97608,77——
SIXE
Energy
SIXE
Energy
SIXE
-1,34%
1 237,98
-16,83
-1,34%
—1 254,811 253,011 253,871 226,33——
SIXI
Industrials
SIXI
Industrials
SIXI
-0,93%
1 744,71
-16,40
-0,93%
—1 761,111 764,271 766,881 744,71——
SIXM
Financials
SIXM
Financials
SIXM
-0,37%
640,18
-2,40
-0,37%
—642,58644,87648,48640,18——
SIXR
Staples
SIXR
Staples
SIXR
-0,18%
849,58
-1,55
-0,18%
—851,13855,66858,75845,56——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-0,23%
217,48
-0,50
-0,23%
—217,98217,98218,65216,88——
SIXT
Technology
SIXT
Technology
SIXT
+1,52%
3 260,69
+48,86
+1,52%
—3 211,833 227,213 268,383 226,55——
SIXU
Utilities
SIXU
Utilities
SIXU
-0,69%
942,45
-6,53
-0,69%
—948,98948,58957,83941,97——
SIXV
Health care
SIXV
Health care
SIXV
-0,52%
1 466,80
-7,72
-0,52%
—1 474,521 479,031 481,041 466,80——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0,22%
2 397,50
+5,38
+0,22%
—2 392,122 396,952 421,222 382,32——
ZEG:FRA
AstraZeneca PLC (US)
€160,90
-0,25%
(-0,40) 1D
30 Apr., 22:00:00 GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for ZEG...
Open
€157,00
High
€161,45
Low
€157,00
Mkt. cap
287,37 mjd
Avg. vol.
729,00
Volume
0,00
52-wk high
€180,45
52-wk low
€115,40
No. of employees
96 k
News stories
From sources across the web
Profile
AstraZeneca plc is a Swedish–British multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, UK. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. The company was founded in 1999 through the merger of the Swedish Astra AB and the British Zeneca Group. Zeneca shareholders received 53.5% of the shares, while Astra shareholders received the remaining 46.5%. Its portfolio includes primary and speciality care, coverage for rare diseases, and a robust global presence across various regions. Since the merger it has been among the world's largest pharmaceutical companies and has made numerous corporate acquisitions, including Cambridge Antibody Technology, MedImmune, Spirogen and Definiens. It has its research and development concentrated in three strategic centres: Cambridge, UK; Gothenburg, Sweden; and Gaithersburg, Maryland, US. AstraZeneca traces its earliest corporate history to 1913, when Astra AB was formed by a large group of doctors and apothecaries in Södertälje. Wikipedia
About AstraZeneca PLC (US)
CEOPascal Soriot
Employees96,1 k
Founded06 Apr. 1999
HeadquartersCambridge, Cambridgeshire, Verenigde Koninkryk
SectorPharmaceutical industry
Websiteastrazeneca.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun. 2025
Sep. 2025
Des. 2025
Mrt. 2026
Revenue
14,46 mjd
15,19 mjd
15,50 mjd
15,29 mjd
Cost of goods sold
2,55 mjd
2,79 mjd
3,17 mjd
2,67 mjd
Cost of revenue
2,55 mjd
2,79 mjd
3,17 mjd
2,67 mjd
Research and development expenses
3,51 mjd
3,63 mjd
3,62 mjd
3,47 mjd
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4,98 mjd
5,20 mjd
5,32 mjd
5,03 mjd
Operating expense
8,42 mjd
8,74 mjd
8,99 mjd
8,31 mjd
Total operating expenses
10,97 mjd
11,53 mjd
12,16 mjd
10,98 mjd
Operating income
3,49 mjd
3,66 mjd
3,35 mjd
4,31 mjd
Other non operating income
-
-
-247,00 m
-
EBT including unusual items
3,13 mjd
3,24 mjd
2,63 mjd
3,91 mjd
EBT excluding unusual items
3,11 mjd
3,32 mjd
3,05 mjd
3,97 mjd
Income tax expense
679,00 m
709,00 m
300,00 m
833,00 m
Effective tax rate
21,71%
21,86%
11,41%
21,28%
Other operating expenses
-72,00 m
-89,00 m
53,00 m
-189,00 m
Net income
2,45 mjd
2,53 mjd
2,33 mjd
3,08 mjd
Net profit margin
16,95%
16,67%
15,00%
20,15%
Earnings per share
2,17
2,38
2,12
1,29
Interest and investment income
65,00 m
85,00 m
135,00 m
73,00 m
Interest expense
-436,00 m
-434,00 m
-155,00 m
-393,00 m
Net interest expenses
-371,00 m
-349,00 m
-20,00 m
-320,00 m
Depreciation and amortization charges
-
-
-
-
EBITDA
4,88 mjd
5,21 mjd
4,11 mjd
5,67 mjd
Gain or loss from assets sale
-21,00 m
-31,00 m
-37,00 m
-34,00 m
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer